Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a classic chronic, systemic autoimmune disease. Its hallmark is symmetric inflammation of the synovial lining, which over time destroys cartilage and progressively erodes bone. The process begins when the immune system loses tolerance to the body's own citrullinated proteins. T and B lymphocytes are activated and produce specific autoantibodies, chiefly rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP). These autoantibodies bind their antigens to form immune complexes that settle in the synovium, switch on the complement cascade and trigger a surge of pro-inflammatory cytokines such as TNF-α, IL-1 and IL-6. The result is new blood vessel growth and proliferation of synovial cells, forming an aggressive, invasive tissue called pannus. Pannus releases protein-digesting enzymes (matrix metalloproteinases, MMPs) that break down joint cartilage directly, and it activates osteoclasts, which erode bone at the joint margins.
At Haute-Derma, we do not see rheumatoid arthritis as just another cause of joint pain. It is a systemic autoimmune syndrome that can affect many organs, including the skin, where it produces its own characteristic lesions. We know that the "window of opportunity" – the first 3–6 months after symptoms begin – is critical: starting immunomodulating drugs during this period can halt joint destruction. Our goals are to diagnose early, fully switch off systemic inflammation, preserve the integrity of your joints and musculoskeletal system, and prevent lasting disability.
Our Approach to Treating Rheumatoid Arthritis
Because RA is chronic and tends to deform joints, Haute-Derma follows a treat-to-target strategy aimed at comprehensive disease control:
- Early diagnosis, even before damage is visible: We combine highly specific biomarkers with high-resolution joint ultrasound to detect synovitis while plain X-rays still look normal.
- Personalized systemic targeted therapy: We plan a treatment pathway that pairs conventional immunomodulating drugs with newer biologic therapies, aiming for complete remission or, at minimum, low disease activity.
- Managing complications across organs: We actively screen for and manage the extra-articular features of RA, including rheumatoid nodules in the skin, rheumatoid vasculitis, interstitial lung disease and the premature atherosclerosis driven by chronic systemic inflammation.
How Rheumatoid Arthritis Is Diagnosed at Haute-Derma
To confirm rheumatoid arthritis and tell it apart from psoriatic arthritis, gout and osteoarthritis, Haute-Derma uses the international ACR/EULAR classification criteria:
Assessing the Characteristic Clinical Features
- Which joints are involved: Painful, warm, swollen joints that are strikingly symmetric on both sides, mainly the small and medium joints – the wrists, the knuckles (metacarpophalangeal joints), the middle finger joints (proximal interphalangeal, PIP) and the joints at the base of the toes. The distal interphalangeal joints, closest to the nails, are usually spared.
- Morning stiffness: Joints feel stiff and hard to move after waking, lasting more than 1 hour and easing only once the patient starts moving or massages the joints.
- Skin and soft-tissue signs: We look for rheumatoid nodules in the skin. These are firm, painless lumps anchored deep in the subcutaneous tissue, typically at pressure points such as the back of the elbow, the back of the head or the Achilles tendon. Their presence points to more severe, progressive disease and high autoantibody levels.
Gold-Standard Investigations
- Serologic immune panel: Measurement of the key autoantibodies and markers:
- Rheumatoid factor (RF): Highly sensitive but only moderately specific.
- Anti-CCP antibodies: Very highly specific (up to 96–98%), allowing RA to be confirmed at a very early stage and flagging patients at high risk of bone erosion.
- Systemic inflammatory markers: Erythrocyte sedimentation rate (ESR) and CRP, which rise in step with acute flares of joint swelling and pain.
- Advanced imaging:
- Musculoskeletal (MSK) ultrasound: High-sensitivity power Doppler picks up increased blood flow in the synovium (synovitis) and tiny bone erosions (micro-erosions) before they show on X-ray.
- Plain hand X-rays: Used to assess later-stage damage such as joint-space narrowing, loss of bone density beneath the cartilage and clear-cut marginal erosions.
How Rheumatoid Arthritis Is Treated at Haute-Derma
Our RA treatment plans start disease-modifying antirheumatic drugs (DMARDs) as early as possible to protect cartilage and bone:
Foundation Therapy (csDMARDs)
- Conventional synthetic DMARDs (csDMARDs): Methotrexate is the anchor drug and the first choice for most people with RA because it controls the disease so well. If the response is inadequate or methotrexate is contraindicated, your doctor will add or use other agents such as sulfasalazine, leflunomide or hydroxychloroquine.
- Corticosteroids and NSAIDs as bridge therapy: Nonsteroidal anti-inflammatory drugs (NSAIDs) or a short course of low-dose oral corticosteroids are used at the outset. They act as a bridge, quickly easing pain and stiffness while the DMARDs build up to effective levels, which usually takes 4–8 weeks. Corticosteroids are always tapered promptly and stopped as soon as possible.
Biologic and Targeted Small-Molecule Therapy (bDMARDs and tsDMARDs)
For RA that does not respond to conventional drugs, or that carries a poor outlook for bone destruction, Haute-Derma uses advanced targeted therapies:
- TNF-alpha inhibitors (e.g., adalimumab, etanercept): Neutralize the main pro-inflammatory cytokine, rapidly calming synovial inflammation.
- IL-6 inhibitors (e.g., tocilizumab): Particularly effective in patients with marked systemic inflammation, fever, anemia of chronic inflammation or a very high CRP.
- B-cell depletion (rituximab): A monoclonal antibody against CD20 on B lymphocytes, removing the cells that produce the faulty autoantibodies (RF, anti-CCP).
- Janus kinase (JAK) inhibitors (e.g., upadacitinib, baricitinib): Newer oral small-molecule drugs that block inflammatory signaling inside cells, achieving remission rates comparable to, or better than, injectable or infused biologics.
